Bicycle Therapeutics Management
Management Kriterienprüfungen 4/4
Bicycle Therapeutics' CEO ist Kevin Lee , ernannt in Sep 2015, hat eine Amtszeit von 8.75 Jahren. Die jährliche Gesamtvergütung beträgt $5.54M , bestehend aus 12.8% Gehalt und 87.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.33% der Aktien des Unternehmens, im Wert von $4.67M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 4.9 Jahre.
Wichtige Informationen
Kevin Lee
Geschäftsführender
US$5.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 12.8% |
| Amtszeit als Geschäftsführer | 8.8yrs |
| Eigentum des Geschäftsführers | 0.3% |
| Durchschnittliche Amtszeit des Managements | 2.4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.9yrs |
Jüngste Management Updates
Recent updates
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
Vergütung im Vergleich zum Markt: KevinDie Gesamtvergütung ($USD5.54M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.66M).
Entschädigung vs. Einkommen: KevinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Kevin Lee (56 yo)
8.8yrs
Amtszeit
US$5,540,400
Vergütung
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Executive Director | 8.8yrs | US$5.54m | 0.33% $ 4.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.3m | |
| Chief Financial Officer | less than a year | US$2.88m | keine Daten | |
| Chief Development Officer | 1.3yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | keine Daten | keine Daten | |
| Chief Operating Officer | 2.4yrs | US$5.98m | 0.021% $ 296.9k | |
| Senior VP | less than a year | keine Daten | 0.0026% $ 36.8k | |
| Chief Technology Officer | 2.4yrs | US$3.07m | 0.070% $ 978.8k | |
| Chief Scientific Officer | 7.4yrs | keine Daten | 0.034% $ 470.5k | |
| General Counsel | 4.2yrs | keine Daten | keine Daten | |
| Senior Vice President of Capital Markets & Corporate Communications | no data | keine Daten | keine Daten | |
| Head of Clinical and Project Management | 8.1yrs | keine Daten | keine Daten |
2.4yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrenes Management: BCYCDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Executive Director | 8.8yrs | US$5.54m | 0.33% $ 4.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.3m | |
| Chairman of Scientific Advisory Board | 6.1yrs | keine Daten | keine Daten | |
| Non-Executive Chairman | 5.3yrs | US$1.06m | 0.031% $ 435.7k | |
| Independent Non-Executive Director | 3.3yrs | US$482.29k | 0.016% $ 217.9k | |
| Independent Non-Executive Director | 4.9yrs | US$526.91k | 0.016% $ 217.9k | |
| Member of Scientific Advisory Board | 3.7yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 3.7yrs | keine Daten | keine Daten | |
| Independent Non-Executive Director | 4.9yrs | US$495.41k | 0.016% $ 217.9k | |
| Member of Scientific Advisory Board | 6.1yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 3.7yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 3.7yrs | keine Daten | keine Daten |
4.9yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter
Erfahrener Vorstand: BCYCDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).